Through the acquisition of Matritech, Inverness Medical can now offer the NMP22 BladderChek test and the NMP22 test kit for the rapid diagnosis and monitoring of early-stage bladder cancer. More commonly seen in men than women, bladder cancer is linked to smoking and exposure to industrial chemicals, with approximately 356,600 new cases reported worldwide each year.
The test detects elevated levels of nuclear matrix protein (NMP22), which are present in the urine of most individuals who have bladder cancer and are detectable even in the early stages of the disease, making it an ideal marker for early diagnosis.
Inverness Medical
www.invernessmedical.com